Press Releases Kancera AB

Equities

KAN

SE0015658570

Delayed Nasdaq Stockholm Other stock markets 02:29:05 13/05/2024 pm IST			5-day change	1st Jan Change
1.83 ^SEK	+6.27%		+26.21%	-59.74%

08/05	Kancera AB Announces Executive Changes	CI
03/05	Kancera AB Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kancera appoints new Chief Scientific Officer and extends management team	08/05	AQ
Kancera meets the primary objectives of the KAND145 clinical phase I study	03/05	AQ
Kancera announces the outcome of the company's rights issue	20/03	AQ
Kancera publishes prospectus in connection with the company’s rights issue	01/03	AQ
Kancera resolves on a rights issue of approximately SEK 121.9 million	23/02	AQ
Interim Report Fourth Quarter 2023, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851	23/02	AQ
Kancera signs license agreement and obtains global commercial rights to the results from the FRACTAL study	23/02	AQ
Kancera presents the statistical analysis of top line data from the FRACTAL study	06/02	AQ
Kancera reports positive top line results from the FRACTAL study	20/12	AQ
Kancera provides operational update in connection with release of financial interim report for third quarter 2023	17/11	AQ
Interim Report Third Quarter July 1 – September 30, 2023 Kancera AB (publ.), org.no. 556806-8851	17/11	AQ
Kancera reports that the phase I study of KAND145 has received regulatory approval	23/23/23	AQ
Kancera announces that the FRACTAL top line results are expected to be presented by the end of December 2023	13/23/13	AQ
Kancera appoints new Chief Medical Officer	01/23/01	AQ
Kancera provides operational update in connection with release of financial interim report for second quarter	18/23/18	AQ
Interim Report Second Quarter April 1 – June 30 2023 Kancera AB (publ.), org.no. 556806-8851	18/23/18	AQ
Newly published research publication confirms the potential for Kancera’s fractalkine blocker KAND567 in cardiovascular disease	24/23/24	AQ
Kancera reports dosing of first patient in the KANDOVA study	19/23/19	AQ
Kancera appoints Peter Selin as new Chief Executive Officer	26/23/26	AQ
Interim Report First Quarter 2023 January 1 – March 31 2023 Kancera AB (publ.), org.no. 556806-8851	19/23/19	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Kancera AB

Equities

KAN

SE0015658570

Press Releases

Filters